| Purpose:To explore the short-term efficacy and safety of endogenous drug embolization microspheres(CalliSpheres)via transcatheter hepatic artery chemoembolization(DEB-TACE)and conventional transcatheter hepatic artery chemoembolization(cTACE)for the treatment of hepatic hypovascular malignancies.Materials and Methods:The data of 39 patients with liver hypothermia and malignant tumors admitted to hangzhou xixi hospital and hangzhou tumor hospital from July 2016 to January 2017 were retrospectively analyzed;DEB-TACE treatment group(group A,18 cases);Traditional TACE treatment group(group B,21 cases).Laboratory data,imaging findings,postoperative complications and adverse reactions were recorded and analyzed before and after treatment for all patients.At least 6 months of follow-up.The efficacy evaluation criteria(mRECIST)for modified solid tumors were used to evaluate the efficacy and compare the changes of liver function in the two groups at 1 week and 1 month before and after interventional therapy,differences in tumor size,recurrence,complications and incidence of adverse reactions after 1?3 and 6 months.Result:There were 39 patients in the two groups,including 18 patients in group A and 21 patients in group B.there were no significant differences between the two groups in gender,age composition,tumor diameter,tumor type,liver function child-pugh classification,portal cancer plug,venous cancer plug,extrahepatic metastasis and previous treatment history.According to the mRECIST standard,the disease remission rate was 61.1%and 57.1%(p=0.045)at 1 month after treatment in group A and group B,and the disease control rate was 83.3%and 80.9%(p=0.043),respectively;3 months disease remission rate respectively 50.0%and 38.1%(p=0.035),disease control rates are 77.8%and 61.9%respectively(p=0.040);6 months disease remission rate respectively 38.9%and 19.15%(p=0.016),disease control rates are 72.2%and 38.1%respectively(p=0.023).There were statistically significant differences in the number of TACE treatments between the two groups during the follow-up period(p=0.045).The operative interval was greater than or equal to 1 month.The two groups of patients had adverse reactions,such as fever,nausea,vomiting and fatigue,after treatment with dda,but the difference was statistically significant(p<0.05).Postoperative length of stay[group A(4.9±2.1d),group B(7.3±5.0d),p=0.029]was statistically significant(p<0.05).After treatment,the patients in group A and group B who needed analgesic drugs accounted for 44.4%and 52.4%,respectively,and the difference was statistically significant(p<0.05).One week after TACE,the levels of Alt,ast,total bilirubin and direct bilirubin were significantly increased in group A and group B,while the levels of platelets and white blood cells were decreased,but the differences between the two groups were statistically significant(p<0.05).All patients showed no serious complications such as biliary tract injury,tumor rupture hemorrhage,hepatic abscess formation and venous tortuosity caused gastrointestinal bleeding.Conclusion:1.The short-term efficacy of DEB-TACE in the treatment of hepatic hypovolemic malignancies is superior to that of cTACE.2.DEB-TACE is safer and more reliable than cTACE in the treatment of hepatic hypovolemic malignancies.3.There was no statistical difference in the postoperative recurrence rate between the two tumors,but there was still recurrence.The form of recurrence after cTACE tended to be the recurrence of the edge of the primary tumor,while deb-tace tended to be the new lesion outside the primary tumor. |
PDF Full Text Request